全文获取类型
收费全文 | 1328篇 |
免费 | 71篇 |
国内免费 | 8篇 |
学科分类
医药卫生 | 1407篇 |
出版年
2023年 | 6篇 |
2022年 | 26篇 |
2021年 | 44篇 |
2020年 | 16篇 |
2019年 | 46篇 |
2018年 | 35篇 |
2017年 | 18篇 |
2016年 | 27篇 |
2015年 | 28篇 |
2014年 | 36篇 |
2013年 | 57篇 |
2012年 | 71篇 |
2011年 | 89篇 |
2010年 | 48篇 |
2009年 | 61篇 |
2008年 | 72篇 |
2007年 | 84篇 |
2006年 | 75篇 |
2005年 | 70篇 |
2004年 | 61篇 |
2003年 | 53篇 |
2002年 | 47篇 |
2001年 | 25篇 |
2000年 | 42篇 |
1999年 | 31篇 |
1998年 | 14篇 |
1997年 | 15篇 |
1996年 | 11篇 |
1995年 | 8篇 |
1994年 | 9篇 |
1993年 | 2篇 |
1992年 | 11篇 |
1991年 | 15篇 |
1990年 | 5篇 |
1989年 | 19篇 |
1988年 | 13篇 |
1987年 | 17篇 |
1986年 | 14篇 |
1985年 | 10篇 |
1984年 | 8篇 |
1983年 | 12篇 |
1982年 | 7篇 |
1981年 | 8篇 |
1980年 | 6篇 |
1979年 | 13篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1976年 | 3篇 |
1975年 | 2篇 |
1974年 | 3篇 |
排序方式: 共有1407条查询结果,搜索用时 15 毫秒
31.
Effect of losartan plus hydrochlorothiazide on nitric oxide status in 'nondipper' hypertensive patients 总被引:1,自引:0,他引:1
Cammarata R Armas-Hernández MJ Hernández-Hernández R Armas-Padilla MC Sosa-Canache B Pacheco B Guerrero J Israili ZH Valasco M 《American journal of therapeutics》2007,14(2):161-165
The objective of this study was to investigate the effects of losartan (100 mg) plus hydrochlorothiazide (HCTZ; 25 mg) on nitric oxide (NO) production and blood pressure (BP) in "nondipper" severe hypertensive patients. Twelve hypertensive "nondipper patients" (6 of each gender) with sitting systolic/diastolic BP of 188.0 +/- 5.2/116.2 +/- 1.2 mm Hg were studied by 24-hour ambulatory blood pressure monitoring (ABPM) after daily administration of 100 mg losartan plus 25 mg HCTZ for a period of 12 weeks. Office and mean 24-hour, as well as mean awake- and sleep-time systolic/diastolic BP, serum NO levels, and urinary excretion of NO were measured after the placebo period (3 weeks) and after 12 weeks of therapy. At the end of the 12-week treatment period, the mean 24-hour systolic/diastolic BP decreased significantly from 158.6 +/- 4.7/102.2 +/- 2.6 mm Hg (placebo period) to 140.3 +/- 4.8/90.9 +/- 3.3 mm Hg (P = 0.001/< or = 0.002). The mean BP (systolic/diastolic) during the waking period was reduced from 159.3 +/- 4.4/103.0 +/- 2.5 mm Hg to 135.0 +/- 4.4/88.2 +/- 3.1 (P < or = 0.007/P < or = 0.002), whereas the mean BP (systolic/diastolic) during the sleeping hours changed from 154.9 +/- 5.3/98.9 +/- 3.1 to 140.9 +/- 4.6 (P = 0.035)/91.7 +/- 3.2 mm Hg (P = 0.035/P = 0.051). Serum NO levels increased from 40.89 +/- 5.69 microM/L (placebo period) to 67.35 +/- 6.96 microM/L (posttreatment; P < or = 0.007), whereas the 24-hour urinary NO excretion did not change significantly (69.71 +/- 3.68 microM/L [placebo period] vs 79.64 +/- 4.25 microM/L [posttreatment]; P < or = 0.16). Urinary clearance of NO also did not change. Serum NO levels increased significantly without a significant change in urinary NO excretion. BP was significantly reduced but without modifying the nondipper pattern in these patients. 相似文献
32.
33.
34.
35.
Pierluigi Toniutto Carlo Fabris Edmondo Falleti Annarosa Cussigh Elisabetta Fontanini Davide Bitetto Ezio Fornasiere Rosalba Minisini Tullia De Feo Francesca Marangoni Mario Pirisi 《Liver international》2008,28(2):257-263
Background/Aims: Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism, being a putative steatogenic factor, may promote liver fibrosis progression in patients with chronic hepatitis C. This study aimed to verify the role of recipient MTHFR polymorphism in favouring graft fibrosis progression in patients with recurrent HCV after orthotopic liver transplantation (OLT). Methods: We studied 63 such patients, followed for >1 year. MTHFR allelic variants were determined by a polymerase chain reaction/restriction fragment length polymorphism method. Results: Recipients carrying the TT genotype had more frequently, 1‐year post‐OLT, homocysteine serum levels >23 μmol/L (P<0.05), serum triglycerides >180 mg/dL (P<0.02) and de novo diabetes mellitus (P<0.05) but not a higher frequency of graft steatosis. Time‐to‐event analysis in reaching an Ishak staging score >2 was performed by stratifying the recipients as follows: (a) patients with donor age ≤45 years, (b) patients with donor age >45 and C/* genotype, and (c) patients with donor age >45 years and TT genotype. A significant linear trend was observed, with increasing frequencies as follows: (a) 8/37, (b) 10/19 and (c) 6/7 (P=0.0005). Conclusion: The MTHFR C677T polymorphism may play a role in influencing liver fibrosis progression in patients with recurrent hepatitis C, in conjunction with donor age, but not via steatosis promotion. 相似文献
36.
37.
Borlandelli Elena Ciaffi Jacopo Festuccia Gianluca Facchini Giancarlo Miceli Marco Brusi Veronica Mancarella Luana Lisi Lucia Di Martino Alberto Faldini Cesare Meliconi Riccardo Ursini Francesco 《Clinical rheumatology》2022,41(2):483-490
Clinical Rheumatology - Osteitis condensans ilii (OCI) is a benign condition characterised by triangular sclerosis of the iliac bone which may mimic radiographic sacroiliitis. Prevalence is... 相似文献
38.
39.
Amirahmadi Roxana Sullivan Scott Britton Noel Siegel Ariel Spiegel Rory Miceli Jennifer Duong Vu Sholander Jeffrey T. Fontaine Magali J. McCurdy Michael T. 《Annals of hematology》2022,101(9):2045-2052
Annals of Hematology - Despite the low risk of peripherally inserted central catheter (PICC) insertion-related bleeding, the practice of administering prophylactic platelets varies greatly.... 相似文献
40.
Ester Badami Rosalia Bus Bruno Douradinha Giovanna Russelli Vitale Miceli Alessia Gallo Giovanni Zito Pier Giulio Conaldi Gioacchin Iannolo 《World journal of gastroenterology : WJG》2022,28(22):2417-2428
Chronic hepatitis C virus (HCV) infection is the principal etiology of cirrhosis and, ultimately, hepatocellular carcinoma (HCC). At present, approximately 71 million people are chronically infected with HCV, and 10%–20% of these are expected to develop severe liver complications throughout their lifetime. Scientific evidence has clearly shown the causal association between miRNAs, HCV infection and HCC. Although it is not completely clear whether miRNA dysregulation in HCC is the cause or the consequence of its development, variations in miRNA patterns have been described in different liver diseases, including HCC. Many studies have analyzed the importance of circulating miRNAs and their effect on cell proliferation and apoptosis. In this Review, we aim to summarize current knowledge on the association between miRNA, HCV and HCC from a diagnostic point of view, and also the potential implications for therapeutic approaches. 相似文献